Novartis Gives Anthropic a Pharma Seat at the Table

The institutional move is cleaner than the marketing language around it. Pharma partnerships usually announce access: data, pilots, platforms, assays. A board seat announces priority. By adding Narasimhan through a public governance action, Anthropic makes life sciences part of how the company wants to be judged, not only where it wants to sell. The outside conversation already tracks the same shift from capability claims to operating loops ^[1]. That is where the real contest sits: the company that shortens the path from experiment to model update gains the advantage before…